How should I manage a 62-year-old male with hypertension (on lisinopril, amlodipine, hydrochlorothiazide) and hyperlipidemia (on rosuvastatin) who presents with new-onset atrial fibrillation with a ventricular rate of 83 beats per minute, shortness of breath, bilateral lower‑extremity edema, and fatigue?

Management of New-Onset Atrial Fibrillation with Heart Failure in a Hypertensive Patient

This patient requires immediate initiation of anticoagulation with a direct oral anticoagulant (DOAC), optimization of rate control with beta-blockers, and aggressive diuresis for heart failure, while continuing his current antihypertensive regimen which already includes an ACE inhibitor that may provide additional benefit for AF prevention.

Immediate Priorities

Anticoagulation for Stroke Prevention

• Start a DOAC immediately (apixaban, rivaroxaban, edoxaban, or dabigatran) rather than warfarin, as DOACs are superior for stroke prevention in AF 1.
• This patient's CHA₂DS₂-VASc score is at least 3 (age 62 = 1 point, hypertension = 1 point, heart failure = 1 point), making anticoagulation mandatory 1.
• Do not add antiplatelet therapy to anticoagulation, as this increases bleeding risk without reducing stroke risk 1.
• Therapeutic anticoagulation must continue indefinitely regardless of whether sinus rhythm is restored, given his thromboembolic risk factors 1.

Rate Control Strategy

• Beta-blockers are the first-line agent for rate control in this patient, particularly given his heart failure presentation 1.
• His current ventricular rate of 83 bpm is already well-controlled, but beta-blockers will provide additional benefit for heart failure management 1.
• Metoprolol succinate 50-400 mg daily or bisoprolol 2.5-10 mg daily are appropriate choices 1.
• Avoid increasing amlodipine or adding non-dihydropyridine calcium channel blockers (diltiazem, verapamil) if his ejection fraction is ≤40%, as these are contraindicated in heart failure with reduced ejection fraction 1.
• Digoxin can be added if beta-blockers alone are insufficient, particularly useful in patients with heart failure 1.

Heart Failure Management

Assess Left Ventricular Function

• Obtain an echocardiogram urgently to determine ejection fraction, as this will guide both rate control medication selection and long-term heart failure therapy 1.
• The bilateral lower extremity edema, shortness of breath, and fatigue suggest volume overload requiring diuresis 1.

Diuretic Therapy

• Increase or optimize his current HCTZ 25 mg or switch to a loop diuretic (furosemide or torsemide) for more aggressive diuresis given symptomatic volume overload 1.
• Monitor renal function and electrolytes closely, particularly potassium, as he is on lisinopril which can cause hyperkalemia 2.

Antihypertensive Medication Considerations

Continue Current ACE Inhibitor

• Maintain lisinopril 40 mg, as ACE inhibitors (and ARBs) have been shown to reduce new-onset AF and AF recurrence in hypertensive patients, particularly those with left ventricular hypertrophy 3, 4, 5.
• In the LIFE study, losartan reduced new-onset AF by 33% compared to atenolol (relative risk 0.67, p<0.001) despite similar blood pressure reduction 4.
• Monitor renal function periodically, as ACE inhibitors can cause acute renal failure, particularly in patients with heart failure or volume depletion 2.
• Watch for hyperkalemia, especially when combined with other medications affecting potassium 2.

Optimize Blood Pressure Control

• His current triple antihypertensive regimen (lisinopril, amlodipine, HCTZ) is appropriate for hypertension with AF 1.
• Do not discontinue amlodipine, as the combination of ACE inhibitor + calcium channel blocker + diuretic is guideline-recommended for difficult-to-control hypertension 1.

Continue Statin Therapy

• Maintain rosuvastatin for cardiovascular risk reduction and lipid management 6.
• Monitor for myalgia, elevated CPK, and liver function abnormalities, though these are relatively uncommon 6.
• Statins may provide modest additional blood pressure reduction (1-2 mmHg), though this is not their primary indication 7.

Rhythm Control Considerations

Cardioversion Decision

• Electrical cardioversion is NOT immediately indicated given hemodynamic stability (rate 83 bpm, no acute instability) 1.
• If cardioversion is considered later for symptom improvement, require either:
  • 3 weeks of therapeutic anticoagulation (INR ≥2.0 for warfarin or adherence to DOAC) before cardioversion, OR
  • Transesophageal echocardiography to exclude left atrial thrombus for early cardioversion 1.
• Continue anticoagulation for at least 4 weeks post-cardioversion and long-term given his risk factors 1.

Antiarrhythmic Therapy

• Rate control is preferred as initial strategy rather than rhythm control, given his age and comorbidities 1.
• If rhythm control becomes necessary for symptom management despite adequate rate control, amiodarone is the safest antiarrhythmic in patients with heart failure or coronary disease 1.
• Avoid flecainide and propafenone if he has heart failure with reduced ejection fraction or coronary artery disease 1.

Critical Monitoring Parameters

Renal Function and Electrolytes

• Check baseline creatinine, BUN, and potassium before intensifying therapy 2.
• Monitor potassium closely given the combination of ACE inhibitor and potential for increased diuretic dosing 2.
• Assess for signs of acute kidney injury, particularly with aggressive diuresis 2.

Bleeding Risk Assessment

• Evaluate and manage modifiable bleeding risk factors as part of shared decision-making for anticoagulation safety 1.
• Do not use bleeding risk scores to withhold anticoagulation, as this leads to under-treatment 1.

Thyroid Function

• Consider checking TSH, as thyroid dysfunction can precipitate AF and rosuvastatin can affect thyroid function 6.

Common Pitfalls to Avoid

• Do not delay anticoagulation while waiting for cardioversion or further workup—stroke risk is immediate 1.
• Do not use reduced-dose DOACs unless specific criteria are met (renal dysfunction, drug interactions, or body weight/age criteria), as underdosing increases thromboembolic events 1.
• Do not add aspirin or other antiplatelet agents to anticoagulation for stroke prevention in AF 1.
• Do not use diltiazem or verapamil for rate control if ejection fraction is ≤40% 1.
• Do not discontinue the ACE inhibitor despite new AF, as it may help prevent AF recurrence and is beneficial for heart failure 4, 8, 9.